Table 1.
Patient and treatment characteristics
| Variable | No. (%) |
|---|---|
| Age, median (range, yr) | 50 (13-75) |
| ECOG performance | |
| 0 | 41 (42.3) |
| 1 | 56 (57.7) |
| Sex | |
| Male | 69 (71.1) |
| Female | 28 (28.9) |
| WHO pathology classification | |
| I (keratinizing) | 5 (5.2) |
| II (non-keratinizing) | 49 (50.5) |
| III (undifferentiated) | 42 (43.3) |
| Unspecified | 1 (1.0) |
| T stage | |
| T1 | 26 (26.8) |
| T2 | 18 (18.6) |
| T3 | 21 (21.6) |
| T4 | 32 (33.0) |
| N stage | |
| N0 | 7 (7.2) |
| N1 | 24 (24.7) |
| N2 | 60 (61.9) |
| N3 | 6 (6.2) |
| TNM staging | |
| III | 60 (61.9) |
| IVa | 31 (32.0) |
| IVb | 6 (6.2) |
| Radiotherapy modality | |
| 3D-CRT | 23 (23.7) |
| IMRT | 74 (76.3) |
| Radiotherapy dose, median (range, Gy) | 69.96 (31.8-72.6) |
| EQD2, median (range, α/β ratio=10) | 70.7 (32.1-73.8) |
| Chemotherapy | |
| None | 5 (5.2) |
| Concurrent | 51 (52.6) |
| Induction+concurrent | 41 (42.3) |
ECOG, Eastern Cooperative Oncology Group; WHO, World Health Organization; TNM, tumor-node-metastasis; 3D-CRT, 3-dimensional conformal radiation therapy; IMRT, intensity-modulated radiation therapy; EQD2, equivalent dose in 2 Gy fractions.